A number of biological assays were then conducted to establish strong antiproliferative activity of this lead molecule against multiple TNBC cells (i.e., MDA-MB-231, MDA-MB-468, BT-549, and Sum-159), HER-2 negative breast carcinoma cell (i.e., MCF-7, T47D), breast carcinoma cell (i.e., BCAP-37), pancreatic carcinoma (i.e., PANC-1, PC-3), melanoma, hepatocarcinoma, lung carcinoma as well as normal human cell lines. Here, ERBB2 is linked to breast carcinoma.